Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer-Reference-Cited by-同舟云学术

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

Published:2018-10-29 Issue:3 Volume:173 Page:585-596
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Vallet Sonia,Fan Fengjuan,Malvestiti Stefano,Pecherstorfer Martin,Sattler Martin,Schneeweiss Andreas,Schulze-Bergkamen Henning,Opferman Joseph T.,Cardone Michael H.,Jäger Dirk,Podar Klaus^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-5022-5/fulltext.html

Reference51 articles.

1. Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. https://doi.org/10.1038/nature11412

2. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337. https://doi.org/10.1038/sj.onc.1210220

3. Vogler M, Dinsdale D, Dyer MJS, Cohen GM (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360–367. https://doi.org/10.1038/cdd.2008.137

4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013

5. Montero J, Letai A (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Diff 25:56–64. https://doi.org/10.1038/cdd.2017.183

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling the Binding of Anticancer Peptides and Mcl-1;International Journal of Molecular Sciences;2024-06-13

2. Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer;Overcoming Cancers Resistant to HER-2 Antibodies;2024

3. A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics;Nature Communications;2023-11-13

4. Reprogramming iPSCs to study age-related diseases: Models, therapeutics, and clinical trials;Mechanisms of Ageing and Development;2023-09

5. A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics;2023-04-14